Chloromycetin Sodium Succinate

In the US, Chloromycetin Sodium Succinate (chloramphenicol systemic) is a member of the drug class miscellaneous antibiotics and is used to treat Anthrax, Bacterial Infection, Brucellosis, Cholera, Glanders, Meningitis, Ornithosis, Plague, Psittacosis, Rabbit Fever and Rickettsial Infection.

US matches:

• Chloromycetin Sodium Succinate

Ingredient matches for Chloromycetin Sodium Succinate

Chloramphenicol

Chloramphenicol succinate sodium (a derivative of Chloramphenicol) is reported as an ingredient of Chloromycetin Sodium Succinate in the following countries:

• United States

International Drug Name Search

Tolperison

Tolperison may be available in the countries listed below.

Ingredient matches for Tolperison

Tolperisone

Tolperisone is reported as an ingredient of Tolperison in the following countries:

• Romania

International Drug Name Search

Deconamine SR Controlled-Release Capsules

Pronunciation: klor-fen-IHR-ah-meen/sue-do-eh-FED-rin
Generic Name: Chlorpheniramine/Pseudoephedrine
Brand Name: Generic only. No brands available.

Deconamine SR Controlled-Release Capsules are used for:

Relieving symptoms of sinus congestion, sinus pressure, runny nose, and sneezing due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.

Deconamine SR Controlled-Release Capsules are an antihistamine and decongestant combination. The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The decongestant promotes sinus and nasal drainage, relieving congestion and pressure.

Do NOT use Deconamine SR Controlled-Release Capsules if:

• you are allergic to any ingredient in Deconamine SR Controlled-Release Capsules


• you have severe high blood pressure, severe heart blood vessel disease, rapid heartbeat, or severe heart problems


• you take sodium oxybate (GHB) or if you have taken furazolidone or a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.

Before using Deconamine SR Controlled-Release Capsules:

Some medical conditions may interact with Deconamine SR Controlled-Release Capsules. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a fast, slow, or irregular heartbeat


• if you have a history of asthma, lung problems (eg, emphysema), adrenal gland problems (eg, adrenal gland tumor), heart problems, high blood pressure, diabetes, heart blood vessel problems, stroke, glaucoma, a blockage of your stomach or intestines, ulcers, a blockage of your bladder, trouble urinating, an enlarged prostate, seizures, or an overactive thyroid

Some MEDICINES MAY INTERACT with Deconamine SR Controlled-Release Capsules. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Beta-blockers (eg, propranolol), catechol-O-methyltransferase (COMT) inhibitors (eg, tolcapone), furazolidone, indomethacin, MAOIs (eg, phenelzine), sodium oxybate (GHB), or tricyclic antidepressants (eg, amitriptyline) because they may increase the risk of Deconamine SR Controlled-Release Capsules's side effects


• Digoxin or droxidopa because the risk of irregular heartbeat or heart attack may be increased


• Bromocriptine or hydantoins (eg, phenytoin) because the risk of their side effects may be increased by Deconamine SR Controlled-Release Capsules


• Guanethidine, guanadrel, mecamylamine, methyldopa, or reserpine because their effectiveness may be decreased by Deconamine SR Controlled-Release Capsules

This may not be a complete list of all interactions that may occur. Ask your health care provider if Deconamine SR Controlled-Release Capsules may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Deconamine SR Controlled-Release Capsules:

Use Deconamine SR Controlled-Release Capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Deconamine SR Controlled-Release Capsules by mouth with or without food.


• Swallow Deconamine SR Controlled-Release Capsules whole. Do not break, crush, or chew before swallowing.


• If you miss a dose of Deconamine SR Controlled-Release Capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Deconamine SR Controlled-Release Capsules.

Important safety information:

• Deconamine SR Controlled-Release Capsules may cause dizziness, drowsiness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Deconamine SR Controlled-Release Capsules with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Do not take diet or appetite control medicines while you are taking Deconamine SR Controlled-Release Capsules without checking with you doctor.


• Deconamine SR Controlled-Release Capsules has pseudoephedrine in it. Before you start any new medicine, check the label to see if it has pseudoephedrine in it too. If it does or if you are not sure, check with your doctor or pharmacist.


• Do NOT take more than the recommended dose or use for longer than prescribed without checking with your doctor.


• If your symptoms do not get better within 5 to 7 days or if they get worse, check with your doctor.


• Deconamine SR Controlled-Release Capsules may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Deconamine SR Controlled-Release Capsules. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.


• Deconamine SR Controlled-Release Capsules may interfere with skin allergy tests. If you are scheduled for a skin test, talk to your doctor. You may need to stop taking Deconamine SR Controlled-Release Capsules for a few days before the tests.


• Tell your doctor or dentist that you take Deconamine SR Controlled-Release Capsules before you receive any medical or dental care, emergency care, or surgery.


• Use Deconamine SR Controlled-Release Capsules with caution in the ELDERLY; they may be more sensitive to its effects.


• Caution is advised when using Deconamine SR Controlled-Release Capsules in CHILDREN; they may be more sensitive to its effects.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Deconamine SR Controlled-Release Capsules while you are pregnant. It is not known if Deconamine SR Controlled-Release Capsules are found in breast milk. Do not breast-feed while taking Deconamine SR Controlled-Release Capsules.

Possible side effects of Deconamine SR Controlled-Release Capsules:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Constipation; diarrhea; dizziness; drowsiness; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor; vision changes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Deconamine SR side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.

Proper storage of Deconamine SR Controlled-Release Capsules:

Store Deconamine SR Controlled-Release Capsules at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Deconamine SR Controlled-Release Capsules out of the reach of children and away from pets.

General information:

• If you have any questions about Deconamine SR Controlled-Release Capsules, please talk with your doctor, pharmacist, or other health care provider.


• Deconamine SR Controlled-Release Capsules are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Deconamine SR Controlled-Release Capsules. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Deconamine SR resources

• Deconamine SR Side Effects (in more detail)
• Deconamine SR Use in Pregnancy & Breastfeeding
• Drug Images
• Deconamine SR Drug Interactions
• Deconamine SR Support Group
• 5 Reviews for Deconamine SR - Add your own review/rating

Compare Deconamine SR with other medications

• Hay Fever
• Sinusitis

Latanoprost

In some countries, this medicine may only be approved for veterinary use.

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

S01EE01

CAS registry number (Chemical Abstracts Service)

0130209-82-4

Chemical Formula

C26-H40-O5

Molecular Weight

432

Therapeutic Category

Glaucoma treatment

Chemical Name

Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate

Foreign Names

• Latanoprostum (Latin)
• Latanoprost (German)
• Latanoprost (French)
• Latanoprost (Spanish)

Generic Names

• Latanoprost (OS: USAN, BAN)
• PHXA 41 (IS: PharmaciaUpjoh)
• XA 41 (IS: Chinoin)

Brand Names

• 9 PM
  Cipla, India



• Gaap Ofteno
  Sophia, Costa Rica; Sophia, Dominican Republic; Sophia, Guatemala; Sophia, Honduras; Sophia, Nicaragua; Sophia, Panama; Sophia, El Salvador; Volta, Chile



• Gaap
  Sophia, Mexico; Sophia, Peru



• Glaucostat
  Valeant, Argentina



• Klonaprost
  Klonal, Argentina; Medigroup, Peru



• Laprost
  Oftalmi, Venezuela



• Latandrops
  Vianex / BIANEΞ, Greece



• Lataneau
  Alapis Pharma, Greece



• Latanopres
  Roemmers, Venezuela



• Latanoprost Dorf
  Pharmadorf, Argentina



• Latanoprost Gen
  Genpharma, Argentina



• Latanoprost Gerolymatos
  png Gerolymatos, Greece



• Latanoprost Pharma-Data
  Pharma-Data, Greece



• Latanox
  Jadran, Croatia (Hrvatska); Procaps, Colombia; Unimed, Peru



• Lataz
  Rafarm, Greece



• Latof
  Saval, Peru; Saval Nicolich, Chile



• Latof-T (Latanoprost and Timolol)
  Saval, Peru



• Latsol
  Antibioticos, Mexico



• Louten T (Latanoprost and Timolol)
  Roemmers, Peru



• Louten
  Pharma Investi, Chile; Poen, Argentina; Roemmers, Peru



• Ocuprost
  Bausch & Lomb, Argentina



• Xalacom Orifarm (Latanoprost and Timolol)
  Pfizer, Denmark



• Xalacom
  Pfizer, Russian Federation



• Xalacom (Latanoprost and Latanoprost)
  Pfizer, United Kingdom



• Xalacom (Latanoprost and Timolol)
  Euro, Netherlands; Gödecke, Germany; Pfizer, Austria; Pfizer, Australia; Pfizer, Belgium; Pfizer, Canada; Pfizer, Switzerland; Pfizer, Germany; Pfizer, Spain; Pfizer, United Kingdom; Pfizer, Croatia (Hrvatska); Pfizer, Indonesia; Pfizer, Ireland; Pfizer, Netherlands; Pfizer, Poland; Pfizer, Slovenia; Pfizer, South Africa; Pharmacia, Slovakia; Stephar, Netherlands



• Xalaprost
  Lansier, Peru



• Xalatan
  Delphi, Netherlands; Euro, Netherlands; Gödecke, Germany; Pfizer, Argentina; Pfizer, Austria; Pfizer, Australia; Pfizer, Bosnia & Herzegowina; Pfizer, Belgium; Pfizer, Burkina Faso; Pfizer, Benin; Pfizer, Canada; Pfizer, Central African Republic; Pfizer, Congo; Pfizer, Switzerland; Pfizer, Cote D'ivoire; Pfizer, Chile; Pfizer, Cameroon; Pfizer, Colombia; Pfizer, Costa Rica; Pfizer, Czech Republic; Pfizer, Germany; Pfizer, Denmark; Pfizer, Ecuador; Pfizer, Estonia; Pfizer, Spain; Pfizer, Finland; Pfizer, France; Pfizer, Gabon; Pfizer, United Kingdom; Pfizer, Georgia; Pfizer, Guinea; Pfizer, Guatemala; Pfizer, Hong Kong; Pfizer, Honduras; Pfizer, Croatia (Hrvatska); Pfizer, Hungary; Pfizer, Indonesia; Pfizer, Ireland; Pfizer, Israel; Pfizer, Iceland; Pfizer, Italy; Pfizer, Japan; Pfizer, Lithuania; Pfizer, Latvia; Pfizer, Madagascar; Pfizer, Mali; Pfizer, Mauritania; Pfizer, Malta; Pfizer, Mauritius; Pfizer, Mexico; Pfizer, Malaysia; Pfizer, Niger; Pfizer, Nicaragua; Pfizer, Netherlands; Pfizer, Norway; Pfizer, New Zealand; Pfizer, Oman; Pfizer, Panama; Pfizer, Peru; Pfizer, Philippines; Pfizer, Poland; Pfizer, Portugal; Pfizer, Romania; Pfizer, Russian Federation; Pfizer, Sweden; Pfizer, Singapore; Pfizer, Slovenia; Pfizer, Senegal; Pfizer, El Salvador; Pfizer, Chad; Pfizer, Togo; Pfizer, Thailand; Pfizer, Tunisia; Pfizer, Turkey; Pfizer, Taiwan; Pfizer, United States; Pfizer, Venezuela; Pfizer, South Africa; Pfizer, Zaire; Pharmacia, China; Pharmacia, Serbia; Pharmacia & Upjohn, Slovakia



• Xalatan (veterinary use)
  Pfizer, Greece; Pfizer Animal Health, United Kingdom



• Xalcom (Latanoprost and Timolol)
  Pfizer, Denmark; Pfizer, Norway; Pfizer, Sweden

International Drug Name Search

Glossary

BAN	British Approved Name
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Prazidec

Prazidec may be available in the countries listed below.

Ingredient matches for Prazidec

Omeprazole

Omeprazole is reported as an ingredient of Prazidec in the following countries:

• Mexico

International Drug Name Search

Capreomycin Sulphate

Capreomycin Sulphate may be available in the countries listed below.

Ingredient matches for Capreomycin Sulphate

Capreomycin

Capreomycin Sulphate (BANM) is known as Capreomycin in the US.

International Drug Name Search

Glossary

BANM	British Approved Name (Modified)

Click for further information on drug naming conventions and International Nonproprietary Names.

Totect

Totect is a brand name of dexrazoxane, approved by the FDA in the following formulation(s):

TOTECT (dexrazoxane hydrochloride - injectable; injection)

• 
  Manufacturer: TOPOTARGET
  
  Approval date: September 6, 2007
  
  Strength(s): EQ 500MG BASE/VIAL ^[RLD]

Has a generic version of Totect been approved?

No. There is currently no therapeutically equivalent version of Totect available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Totect. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Treatment of accidental extravasation of anthracyclines
  Patent 6,727,253
  Issued: April 27, 2004
  Inventor(s): Seppo W.; Langer & Peter B.; Jensen & Maxwell; Sehested
  Assignee(s): Antianthra APS
  The present invention relates to a method for pharmacological treatment of accidental extravasation of topoisomerase II poisons, such as anthracyclines. In particular, the invention relates to the use of a topo II catalytic inhibitor, such as the bisdioxopiperazine ICRF-187, for the treatment of an accidental extravasation of a topoisomerase II poison. A method for treatment of such extravasation of a topoisomerase poison such as the anthracyclines, daunorubicin, doxorubicin, epirubicin, or idarubicin is disclosed.
  
  Patent expiration dates:
  
  
  • March 13, 2020
    
    ✓ 
    Patent use: TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • September 6, 2010 - NEW PRODUCT
  
  
  • September 6, 2014 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Totect Consumer Information (Drugs.com)
• Totect Consumer Information (Cerner Multum)
• Totect Advanced Consumer Information (Micromedex)
• Dexrazoxane Consumer Information (Wolters Kluwer)
• Dexrazoxane Consumer Information (Cerner Multum)
• Dexrazoxane Intravenous Advanced Consumer Information (Micromedex)
• Dexrazoxane Hydrochloride AHFS DI Monographs (ASHP)

Calcimagon D

Calcimagon D may be available in the countries listed below.

Ingredient matches for Calcimagon D

Calcium Carbonate

Calcium Carbonate is reported as an ingredient of Calcimagon D in the following countries:

• Spain

Colecalciferol

Colecalciferol is reported as an ingredient of Calcimagon D in the following countries:

• Spain

International Drug Name Search